ArticleJCEM case reports2025
Exogenous Insulin Antibody Syndrome: A Rare Cause of Extreme Insulin Resistance Treated With High-dose Corticosteroids.
Article in JCEM case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical characteristics and individualized treatment strategies for children with type 1 diabetes and exogenous insulin antibody syndrome: a retrospective case series and literature review.Frontiers in endocrinology · 2026Review
- Insulin Resistance at the Crossroads of Metabolic Inflammation, Cardiovascular Disease, Organ Failure and Cancer.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exogenous insulin antibody syndrome is a rare condition characterized by extreme insulin resistance caused by antibodies that neutralize the action of insulin. An 80-year-old woman with type 1 diabetes mellitus was transferred to an Australian quaternary hospital with refractory hyperglycemia and diabetic ketoacidosis despite receiving >300 units of insulin daily. Laboratory testing revealed a very high insulin antibody titer of 6758 U/mL (6758 kU/L)(<0.4 U/mL; <0.4 kU/L). Plasmapheresis was considered but was not pursued because of hemodynamic instability, multiple comorbidities and frailty. Treatment with high-dose methylprednisolone at 1 mg/kg for 5 days and 500 mg of mycophenolate mofetil twice daily, followed by a tapering regimen of prednisone, resulted in a significant improvement in extreme insulin resistance. The total daily dose of insulin after treatment returned to a baseline of approximately 70 units and insulin antibody titers were reduced by 8-fold. Remission was maintained for more than 2 years until the patient died of an aggressive squamous cell carcinoma of the buccal mucosa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.